ALKBH3 upregulation has been associated with poorer prognostic outcomes in several cancers, including non-small-cell lung cancer [51], pancreatic cancer [52], renal cell carcinoma [53], and hepatocellular carcinoma [54]. This evidence concerns the gene ALKBH3 and pancreatic neoplasm.